IBM's October Earnings Test: Can Mainframe Stabilization Outweigh a 21% Annual Slide?

IBM shares have fallen 21% year-to-date as investors weigh weak mainframe demand against quantum and AI progress ahead of October earnings.

IBM shareholders are heading into a pivotal stretch. After months of share-price erosion, the Armonk-based technology giant must now convince a skeptical market that it can bridge the gap between its legacy hardware operations and its ambitious growth bets.

The stock finished Wednesday's session at EUR 205.75, translating to a year-to-date decline of 21%. That retreat has been closely tied to the company's recent operational performance. Following a soft prior quarter and cautious commentary on enterprise customer spending, investors are hunting for hard evidence of a fundamental turnaround. While IBM has rolled out a string of technological achievements, the share price continues to reflect lingering doubt. The question now facing market participants: does the current level represent a buying opportunity, or do the risks outweigh the rewards ahead of the next earnings release?

Infrastructure Revenue Holds the Key

The single most important variable for IBM's near-term trajectory sits within its infrastructure division. Group revenue grew just 1% in the second quarter, dragged down by a 7% revenue decline in the Infrastructure segment. CEO Arvind Krishna attributed that setback to weakness in Z-series mainframe computers and a shift in capital spending priorities among large enterprise clients. Many corporate customers reallocated budgets, causing delays in traditional hardware purchases.

For market watchers, this segment is the fulcrum. Unless the mainframe business stabilizes, IBM's initiatives in other areas risk being overshadowed. Should the company overcome customer spending hesitation, the broader picture could brighten quickly.

Quantum and AI Partnerships Build the Bull Case

Supporting the optimistic scenario are tangible advances in emerging technologies and research collaborations. On September 10, IBM and NASA jointly unveiled the Lunar Foundation Model, one of the first publicly available building blocks for analyzing lunar data. The project underscores IBM's technical prowess in complex AI applications for scientific missions.

That same day, IBM and Lockheed Martin announced plans for a quantum innovation hub at ETH Zurich, anchored by Switzerland's first IBM quantum computer. The initiative rests on an offset agreement with armasuisse, the Swiss federal office for armaments, strengthening IBM's international footprint in quantum computing. A partnership with Red Hat on the Lightwell initiative further extends the company's push into automated software solutions for enterprise supply chains.

Separately, subsidiary Anderon closed an agreement with the US Department of Commerce for $1 billion in CHIPS funding to advance research into a pure-play quantum foundry on American soil. And in early September, a team comprising IBM, the Cleveland Clinic and RIKEN reached the finals for the ACM Gordon Bell Prize after successfully computing a protein with 12,635 atoms on quantum computers.

If management can convert this innovation momentum into measurable revenue growth, the stock holds meaningful catch-up potential.

Management's 2026 Targets Set the Bar

The central question for investors concerns the financial viability of these technological initiatives. Research breakthroughs alone no longer suffice to sustain a legacy company's valuation on Wall Street. Shareholders want proof that IBM can shape market-ready products and scalable services from its scientific projects. The tension between costly basic research and dependable operating profitability increasingly defines the debate over the company's strategic direction.

According to a Reuters report, management has guided for currency-adjusted revenue growth of 4% to 5% for fiscal 2026, alongside an increase in free cash flow of roughly $1 billion year over year. Those benchmarks form the operational yardstick by which IBM will be judged.

Legal Headwinds and Spending Discipline Weigh on the Outlook

Countering the recovery narrative are concrete risks that could widen the downside. The company faces allegations of potentially misleading financial disclosures tied to missed revenue targets. While the outcome of such legal proceedings remains open, cases of this nature routinely erode market confidence.

Add to that the fundamental industry risk: if large customers continue reallocating budgets toward other priorities, the hardware division faces a prolonged dry spell. A renewed decline in the high-margin mainframe segment would hit the company hard.

Chart Levels and the October Catalyst

For the investment decision ahead, the interplay between technical markers and operational milestones offers reliable orientation. As long as the stock defends its 50-day moving average at EUR 199.96, the chance of a technical stabilization remains intact. A sustained break below that support zone would likely accelerate the broader downtrend and trigger fresh selling pressure.

On the operational side, meeting annual targets will determine the stock's direction. Investors should watch closely whether management can confirm and deliver on its 4% to 5% currency-adjusted revenue growth goal. The company's showing at the 2026 ACM Gordon Bell Prize will also offer important signals about its technological leadership. Should the hoped-for commercial breakthroughs fail to materialize, the stock will lack the fundamental fuel for a sustained recovery.

The upcoming October earnings report will provide detailed insight into actual demand trends and progress on operational stabilization. Clear conditions can be drawn for the stock's path forward. So long as the core business holds steady and no further Z-mainframe declines are reported, the shares have room to recover. But if infrastructure demand falters again — or if persistent customer budget shifts force further guidance cuts — the correction is likely to continue. That October date stands as the decisive catalyst.